Page 30 - Read Online
P. 30

Berardo et al. J Transl Genet Genom 2020;4:22-35  I  https://doi.org/10.20517/jtgg.2020.02                                            Page 29
                                  [49]
               In 2009, Duncan et al.  described the first variant in COQ9 (c.730C>T, p.Arg244*), in a patient from an
               apparently non-consanguineous Pakistani family, who presented with neonatal lactic acidosis, intractable
               seizures, global developmental delay, microcephaly, dystonia, left ventricular hypertrophy, and renal tubular
                         [50]
               dysfunction .
                             [51]
               Danhauser et al.  described another infant carrying a homozygous splice-site variant c.521+1del, p.(Ser127_
               Arg202del) in COQ9, manifesting with neonatal encephalopathy with hypotonia, poor breathing, and severe
               lactic acidosis with symmetrical hyperechoic signal alterations in the basal ganglia, suggestive of neonatal
               Leigh-like syndrome. The patient subsequently developed seizures and recurrent episodes of apnea and
               bradycardia and died at 18 days of life.

                                [52]
               In 2018, Smith et al.  reported four siblings, who presented prenatally with an unknown and an ultimately
               lethal condition characterized by intrauterine growth retardation, oligohydramnios, variable dilated
               cardiomyopathy, anemia, abnormal appearing kidneys, and autopsy brain findings suggestive of Leigh
               disease. The patients had the variants c.521+2T>C and c.711+3G>C in COQ9, which cause in-frame deletions
               (p.Ser127_Arg202del and p. Ala203_Asp237del).

               In 2019, a novel frameshift c.384delG (Gly129Valfs*17) homozygous mutation was reported in a 9-month-old
               girl, born from consanguineous parents of Pakistani origin, presenting with growth retardation, microcephaly,
               and seizures. She was born at 38 weeks gestation, weighed 2000 g, after an uncomplicated pregnancy, and was
               hospitalized for 3 days due to respiratory distress. At age 4 months, she had sustained clonic seizures. Physical
               examination showed microcephaly, truncal hypotonia, and dysmorphic features. Abdominal ultrasonography
               revealed cystic kidneys. Non-compaction of the left ventricle was detected in echocardiography.
               Cranial MRI showed hypoplasia of the cerebellar vermis and brain stem, corpus callosum agenesis,
               and cortical atrophy. CoQ  supplementation (5 mg/kg/day) was started when she was 10 months old.
                                      10
               Despite increasing the dose to 50 mg/kg/day after the molecular diagnosis, no neurological improvement
                          [53]
               was observed .

               DIAGNOSIS OF EARLY ONSET MULTISYSTEMIC PHENOTYPE OF PRIMARY COQ
                                                                                              10
               DEFICIENCY
               Early onset primary CoQ  deficiency is clinically heterogeneous, and genotype-phenotype correlation
                                      10
               is based on a limited number of cases [9,10] . Four phenotypic groups can be defined: (1) SRNS, isolated or
               with neurological involvement, associated with defects in PDSS2, COQ2, COQ6, or COQ8B (the latter
               with later age-at-onset); (2) encephalomyopathy, hypertrophic/dilated cardiomyopathy, lactic acidosis, and
               tubulopathy with defects in PDSS2, COQ2, COQ7, or COQ9; (3) neonatal cardio-encephalopathies with
               COQ2, COQ4, or PDSS1; and (4) pure neurological syndromes, including isolated or combined Leigh
               syndrome, ARCA, and refractory epilepsy, in association with defects in COQ2, COQ4, COQ5, COQ7, or
               COQ9 [Table 1 and Figure 2] [9,10] .


               In general, clinical features alone are insufficient to definitively diagnose CoQ  deficiency or to distinguish
                                                                                 10
               between primary and secondary CoQ  deficiencies, or even from other mitochondrial conditions. Therefore,
                                               10
               evaluation of patients with suspected CoQ  deficiency relies on genetic or biochemical studies. If the
                                                     10
               clinical picture and/or family history raise the possibility of a metabolic/genetic condition, WES, including
               sequencing of mitochondrial DNA, if available, should be considered the first step. However, only 35% of
                                               [54]
               Mendelian diseases are solved by WES  because the majority of undiagnosed cases are subject to limitations
               in variant‐calling and prioritization, as well as inability to detect intronic and regulatory pathogenic variants.
               WGS enables complete coverage of the genome; however, interpretation is often hindered by difficulty in
               prioritization of the vast numbers of variants detected and our incomplete understanding of the non-coding
   25   26   27   28   29   30   31   32   33   34   35